Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183456 | 0.90 | CYP1A2 (0.58) | CYP1A2MEN1KMT2AGAACYP2C19 | |
| SCHEMBL16471735 | 0.89 | CYP1A2 (0.57) | CYP1A2MEN1KMT2AGAANPC1 | |
| Bromide SCHEMBL4313894 | 0.89 | CYP1A2 (0.57) | CYP1A2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL469419 | 0.88 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2D6L3MBTL1HDAC8 | |
| Bromide SCHEMBL19587023 | 0.86 | CYP1A2 (0.55) | CYP1A2CYP2C19CYP2D6L3MBTL1HDAC8 | |
| Bromide SCHEMBL19585473 | 0.86 | CYP1A2 (0.55) | CYP1A2CYP2C19CYP2D6L3MBTL1HDAC8 | |
| Bromide SCHEMBL19585520 | 0.86 | CYP1A2 (0.55) | CYP1A2CYP2C19CYP2D6L3MBTL1HDAC8 | |
| SCHEMBL13914452 | 0.84 | CYP1A2 (0.58) | CYP1A2MEN1KMT2AGAAALDH1A1 | |
| Acetic Acid SCHEMBL4317382 | 0.84 | CYP1A2 (0.54) | CYP1A2MEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL8054329 | 0.80 | MEN1 (0.52) | CYP1A2MEN1KMT2AGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527805-B2 | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-27 | — | — | US | disclosed |
| US-9527805-B2 | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-27 | — | — | US | disclosed |
| US-20140011857-A1 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011857-A1 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2012034116-A2 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-15 | — | — | WO | disclosed |
| US-7851457-B2 | antianthrax agent; low molecular weight derivataive of cyclodextrin with seven D-glucose units, that block the pore formed by protective antigen and inhibit anthrax toxin action | INNOVATIVE BIOLOGICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090023210-A1 | B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN | PINNACLE PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090005343-A1 | B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN | PINNACLE PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005343-A1 | B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN | ANTXR2, CANX, SLC47A2 | CYP1A2 3067/4885MEN1 3770/4885KMT2A 3975/4885 |
| US-20140011857-A1 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | KDM1B, DOT1L, EHMT1 | CYP1A2 3999/4885MEN1 2450/4885KMT2A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.